Division of Teva Pharmaceutical Industries Ltd.
Latest From Actavis Generics
An attempt by Accord, Actavis, Apotex, Kabi and Mylan to overturn a US patent protecting Sanofi’s Jevtana cabazitaxel cancer drug until 2021 has failed. And claims in a patent running until 2031 could yet return to haunt the generics firms.
Teva has registered a further impairment of almost $500m, largely linked to the value of assets acquired when it took over Actavis in 2016. Meanwhile, sales slid by 15% to $4.3bn in the first quarter.
Amneal gets a new CSO, Acino restructures its board under a new chair, the AAM adds an assistant general counsel and the British Biosimilars Association names a vice-chair, as well as other people movements from around the generics, biosimilars and value-added medicines industries.
Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
- Contact Info
Phone: (905) 814-1820
6733 Mississauga Road
Mississauga, L5N 6J5
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.